Invesaro

Stocks Health care LSTA

NASDAQ · Health care

Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics, Inc. brought in $100K of revenue over the twelve months to June 30, 2026, down 90.7% from a year earlier. It posted a net loss of $14.6M. In fiscal 2024 capital spending exceeded operating cash flow by $16M. At June 30, 2026 it held $10.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price
$1.58
+5.33% on the day · September 25, 2026
52-week range $0.99 to $5.07
Market cap
$14.2M
Revenue (last 12 months)
$100K
-90.7% year on year
Net margin
-14,621.0%

What Lisata Therapeutics, Inc. does

Lisata Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LSTA.

Revenue and profit by year

Revenue
FY22: $0 $0 FY22FY23: $0 $0 FY23FY24: $1M $1M FY24FY24: $170K $170K FY24
Net income
FY18: -$16.2M -$16.2M FY18FY19: -$19.4M -$19.4M FY19FY20: -$8.2M -$8.2M FY20FY21: -$27.5M -$27.5M FY21FY22: -$54.2M -$54.2M FY22FY23: -$20.8M -$20.8M FY23FY24: -$20M -$20M FY24FY24: -$16.6M -$16.6M FY24

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2024$170K-$18.2M-$16.6M-$1.91-$16M
2024$1M-$22.4M-$20M-$2.40-$19.4M
2023$0-$25.7M-$20.8M-$2.58-$20M
2022$0-$57.6M-$54.2M-$10.47-$21.5M
2021n/a-$29.1M-$27.5M-$7.45-$22.3M
2020n/a-$19.1M-$8.2M-$7.90-$8.8M
Next report expected around October 19, 2026.

Estimated from its filing rhythm: about 74 days after its last report of August 6, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where LSTA ranks in Health care

Revenue$170K
#612 of 646 in Health care · Bottom 5%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

Fiscal yearPer sharePaid outOf profit
2014n/a$0n/a
2013n/a$0n/a
2012n/a$327.7Kn/a
2011n/a$0n/a
2011n/a$222.9Kn/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Lisata Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 17, 2026
  2. August 26, 2026
  3. August 6, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.32 versus -$0.54.
  4. August 4, 2026
  5. July 28, 2026
  6. July 24, 2026
  7. July 21, 2026
  8. July 17, 2026
  9. July 17, 2026
  10. July 17, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on January 13, 2026. Insider transactions on SEC

Who owns LSTA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Branham Justin Earl13G, passive 5.1% 462,149 August 26, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about LSTA

What does Lisata Therapeutics, Inc. do?

Lisata Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LSTA.

Is Lisata Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $14.6M on revenue of $100K.

How much revenue does Lisata Therapeutics, Inc. make?

Over the twelve months to June 30, 2026 Lisata Therapeutics, Inc. reported revenue of $100K. That is 90.7% less than a year earlier.

When did Lisata Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the acquisition or sale completed from September 17, 2026.

Similar companies

Compare LSTA with

Compare LSTA with any company

Follow LSTA

Get an email when Lisata Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow LSTA: get an email when it files

Where the numbers come from

Financial figures are the values Lisata Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.